The fastest or first half price reduction of Chinese patent medicine

The drug price evaluation center of the national development and Reform Commission (NDRC) held a pre evaluation meeting on the prices of Chinese patent medicines in gynecology, ophthalmology, otorhinolaryngology, orthopedics and dermatology in Beijing on the 13th, according to a public announcement on the 19th This is considered to be the latest signal of the coming trend of Chinese patent medicine price reduction It is understood that at the end of last year and the beginning of this year, the national development and Reform Commission frequently held seven price review meetings on Chinese patent medicines, covering all kinds of Chinese patent medicines in the 2010 medical insurance catalog The newly completed price pre review meeting is considered by the industry that the price reduction trend of Chinese patent medicine is approaching day by day, and it is likely that the price adjustment policy will be issued in the first half of the year News from our newspaper (reporter Tu Duanyu) since January 7, 2013, after the national development and Reform Commission announced the completion of the price adjustment of Western medicine in the medical insurance catalog, the news that Chinese patent medicine will face the price reduction tide has been repeatedly raised The real acceleration of rhythm started at the end of 2013 The evaluation center reviewed 18 kinds of Chinese patent medicines, such as expectorant, Fuzheng and tumor, from December 3 to 6 On February 13, the remaining five varieties were reviewed It is said that the decline of traditional Chinese medicine injection or the biggest industry rumor, at that time, traditional Chinese medicine injection will face the biggest price cut, which is believed to be due to its high profit margin It is understood that the average profit of traditional Chinese medicine injection has reached 50%, and many of them have entered the catalogue of basic drugs and general medical insurance "This year, traditional Chinese medicine injection may face two major practical problems, one is the expectation of substantial price reduction, the other is that clinical use will become more and more cautious." Long hengmu, director of the Department of traditional Chinese medicine of the otolaryngology Research Institute of Guangdong Armed Police Hospital, said that the clinical selection will be more strict due to the frequent exposure of adverse events of traditional Chinese medicine injection before But many people in the industry do not think that this price reduction will bring enterprises a "sharp pain" "From the previous western medicine price reduction, we can see the style of drug price adjustment by the national development and Reform Commission Enterprises are basically able to bear it and have a certain living space, so this time, it is still possible to be" gentle ", not to hurt the muscles and bones so that enterprises will lose money and close down." One industry observer estimates that.